Plain-English translation of NCT07251998 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase 2 trial testing whether ICP-332, a new experimental medication, can safely and effectively treat moderate to severe plaque psoriasis. Researchers will compare three different doses of the medication against placebo (an inactive pill) to see which works best and has the fewest side effects. About 172 people will participate.
Many people with moderate to severe psoriasis need better treatment options because current therapies don't work well enough for everyone. This trial is exploring whether this new medication could offer a more effective way to control the disease.
You likely qualify if…
You likely don't qualify if…
If you join, you will be randomly assigned to take either one of three doses of the medication or a placebo pill. You will take your assigned treatment for a set period while researchers monitor your psoriasis symptoms through regular visits and blood tests. The study will measure how much your skin improves, check for side effects, and track how your body processes the medication.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Enrollment target
~172 participants
Started
December 2025
Primary completion
October 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Molly Lin
Shanghai Dermatology Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.